Suchergebnisse - Jacob M. Rowe

CPX‐351 +/− gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable‐intermediate risk, FLT3‐ITD negative, AML: A pilot study Autoría: Chezi Ganzel, Avraham Frisch, Ofir Wolach, Yakir Moshe, Baher Krayem, Neta Dor, Etti Broide, Emmanuel Benayoun, Jacob M. Rowe, Yishai Ofran